Tan et al 2025 — Visual cortex → thalamic LP circuit modulates pain

One-paragraph summary

Mechanism paper identifying the medial secondary visual cortex (V2M) glutamatergic projection to the lateral posterior thalamic nucleus (LP) as a previously-uncharacterized pain-modulation circuit. In mice, V2M glutamatergic neurons (V2M^Glu) are activated by peripheral stimulation under normal conditions. Optical inhibition of unilateral V2M^Glu decreases bilateral nociceptive sensitivity; optical activation increases sensitivity and induces aversive emotional behavior. Anatomical tracing shows V2M^Glu sends dense synaptic projections to the lateral posterior thalamic nucleus (LP) and lateral dorsal thalamic nucleus (LD), but only optical manipulation of V2M^Glu terminals in LP, not LD, affects bilateral pain perception — establishing LP as the critical downstream target. Following partial sciatic nerve ligation (PSL), V2M^Glu exhibits hyperactivity (increased spontaneous spike frequency and heightened responsiveness to stimulation). Inhibiting V2M^Glu, or inhibiting V2M^Glu terminals specifically in LP, alleviates PSL-induced mechanical allodynia, thermal hyperalgesia, and pain-related negative affective states. The authors propose targeting V2M^Glu and related circuits as therapeutic strategy for neuropathic pain. For the project, this paper provides the missing-link neural-circuit mechanism for how visual input could modulate pain — V2M is in the visual cortex but projects to a thalamic pain-relevant region. Combined with Dai et al 2025 mini-review (which implicates lateral geniculate nucleus → descending-inhibition pathway), the visual cortex → thalamic gating framework is now anchored at the circuit level. Bridges Hypothesis 2's network-FC framework (Hou 2026 thalamocortical decoupling in FM) to the green-light cure-path arm.

Claims as triples

• v2m_glutamatergic_circuit — modulates → widespread_pain [evidence: optical inhibition reduces bilateral nociceptive sensitivity; confidence: emerging]
• v2m_glutamatergic_circuit — present_in → thalamus [evidence: dense synaptic projections from V2M^Glu to LP nucleus; confidence: established]
• thalamus — modulates → central_sensitization [evidence: V2M-LP circuit hyperactivity in PSL neuropathic pain; LP-specific manipulation rescues; confidence: emerging (reinforces existing edge)]
• green_light_exposure — bridges → v2m_glutamatergic_circuit [evidence: visual cortex → thalamic LP pain modulation provides candidate substrate for green-light's central analgesia (inferential connection); confidence: bridging]

Methods note

Mouse model. Optogenetic and chemogenetic manipulation of V2M glutamatergic neurons. Anatomical tracing (likely AAV-based retrograde + anterograde tracers) to map V2M^Glu projections. Neuropathic-pain model: partial sciatic nerve ligation (PSL). Pain readouts: von Frey hair (mechanical), thermal hyperalgesia, affective behavior assays. In vivo electrophysiology: V2M^Glu spike frequency baseline and stimulation response.

Limitations

• Mouse model; translation to human visual cortex → thalamic LP function is by structural analogy. Mouse and human V2M / LP organizations differ in detail though the overall framework is conserved.
• Neuropathic-pain model (PSL), not FM model. Whether V2M^Glu hyperactivity operates in FM specifically is open. Could be tested in FM rs-fMRI or PET imaging data via post-hoc analysis of V2M-LP functional connectivity.
• Optogenetic / chemogenetic manipulation is not human-translatable as a therapy. The paper's translational value is identifying a circuit target, not a clinical intervention. Green-light exposure may be one (non-circuit-specific) human-translatable proxy intervention.
• No green-light experimental arm — the connection from this paper to green-light therapy is inferential, made in this ingestion based on the circuit's visual-input convergence.

Open questions raised

• Does V2M-LP functional connectivity differ in FM patients vs. controls? Could be tested in existing rs-fMRI datasets (Hou 2026 cohort would be ideal).
• Does green-light therapy modulate V2M-LP connectivity in FM patients? Pre-post green-light functional-imaging study would directly test this.
• Is the V2M-LP circuit the same as the lateral-geniculate → descending-inhibition pathway proposed in Dai et al 2025, or are these parallel circuits both involved in visual-input pain modulation?

Triangulation notes

• Provides the candidate neural-circuit mechanism for the v0.3.1 §12.7 green-light arm. Until now the arm has had molecular mechanism (endocannabinoid, N-acyl-glycines per O'Brien 2025) and consolidating framework (Dai et al 2025) but not a specific neural circuit. This paper supplies V2M → LP as the candidate circuit, with rigorous optogenetic / chemogenetic dissection.
• Bridges to Hypothesis 2 — Hou 2026 documents thalamocortical decoupling in FM rs-fMRI. The Tan et al circuit places thalamic LP (a candidate decoupled region) downstream of visual cortex (V2M). A unified read: FM patients have V2M-LP circuit hyperactivity (mirroring the PSL neuropathic-pain finding), and green-light input may rescue by modulating V2M-LP signaling.
• Compatible with Coluzzi 2025 TSPO-PET microglial-activation findings in nociplastic pain — microglial activation could be downstream of V2M-LP hyperactivity, or independent.
• Opens a new entity class candidate: neural-circuit-level entities, currently absent from the ontology grammar. The project's mechanism class captures broad pathways; specific circuits like V2M-LP are not currently representable except as descriptive notes.

Bridges

• B21 strengthened — green-light therapy ↔ FM via candidate V2M-LP circuit modulation.
• New candidate B23 — visual-cortex-to-thalamic-pain-circuit modulation as therapy class. Could include green-light therapy, visual-cortex transcranial magnetic stimulation, visual-cortex-targeted neurofeedback. Drug-class-defined bridge for visual-modality pain therapies.